WuXi AppTec
VC Fund
Shanghai, China
WuXi AppTec is a VC fund in Shanghai focused on Biotechnology and Health Care. WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve theproductivity of advancing healthcare products through cost-effective and efficient solutions,With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec's open-access platform is enabling more than 3,900 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated".
- Total investments:
- 49
- Last investment:
- Lead investor:
- 20%
- Fund size:
- $250M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries WuXi AppTec invests in
Stages WuXi AppTec invests in
Countries WuXi AppTec invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 9 contacts → | |||
Round size
- Series A
- $6M–$90M
- Series B
- $21M–$130M
- Series C
- $30M–$187M
Investment Focus
Industry
- Biotechnology 33 (67%)
- Health Care 23 (47%)
- Pharmaceutical 22 (45%)
- Medical 11 (22%)
- Artificial Intelligence 8 (16%)
Stage
- Series A 18 (37%)
- Series B 16 (33%)
- Series C 4 (8%)
- Series D 3 (6%)
- Venture - Series Unknown 2 (4%)
Country
- United States 21 (43%)
- China 13 (27%)
- Israel 1 (2%)
- Taiwan 1 (2%)
- Germany 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Edward Hu
Co-CEO
|
Co-CEO | Total investments: 5 | Find email | |
Ellis Chu
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email | |
Ge Li
Founder, Chairman and CEO
|
Founder, Chairman and CEO | Total investments: 0 | Find email | |
|
Juan Lagos
Associate Director Upstream Process Development
|
Associate Director Upstream Process Development | Total investments: 0 | Find email | |
Lina Huang
Senior Director Accounting
|
Senior Director Accounting | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
D3 Bio
|
D3 Bio is a globally focused biotechnology company focusing on developing and registration of innovative medicines in oncology and immunology. At D3 Bio, our new medicine development approach is fundamentally differentiated. We do not just only start with science in the lab. First, we pinpoint the greatest unmet patient and market needs – whereexisting standard-of-care approaches yield unsatisfactory clinical outcomes. Then we take those insights into the lab to guide the identification of fit for purpose science and technology and define our drug development path. | $62M / Series A / Apr 08, 2024 | |
|
Bioyond Tech
|
Bioyond Tech utilizes robotics and artificial intelligence technology to provide a new generation of modular products and automation solutions for the life sciences sector. | $29.1M / Series A / Apr 03, 2023 | |
ShouTi
|
ShouTi specializes in the discovery and development of drugs against a type of targets called GPCR. The company develops drugs focused on novel small molecules for multiple unmet medical needs. ShouTi is currently operating in Stealth mode. | $100M / Series B / Oct 20, 2021 | |
Structure Therapeutics
|
Structure Therapeutics creates life-changing medicines for patients using advanced computational and structure-based technology. Our platform combines the latest advancements in computational chemistry, visualization of molecular interactions, and data integration to design orally available, superior medicines that overcome current limitations inbiologic and peptide drugs. We are advancing our clinical-stage pipeline of differentiated, efficacious and safe treatments focused on chronic diseases with high unmet need, including cardiovascular, metabolic and pulmonary conditions. At Structure, our team’s deep experience with complex biological targets and mechanisms, structure-based drug design, and global drug discovery and development enables our bold vision: to design and develop world-class medicines with tremendous patient impact and broad commercial opportunity. | $100M / Series B / Oct 20, 2021 | |
Stemirna
|
Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science. The company currently has more than a dozen of independently-developed mRNA drug projects, focusing on the fields of mRNA-based personalized cancer vaccines, mRNA vaccines for infectious disease, protein defects diseases, andgenetic diseases, providing cure and solutions for cancer and infectious diseases, better serving patients. | $170.1M / Jun 03, 2021 | |
|
Stemirna
|
Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science. The company currently has more than a dozen of independently-developed mRNA drug projects, focusing on the fields of mRNA-based personalized cancer vaccines, mRNA vaccines for infectious disease, protein defects diseases, andgenetic diseases, providing cure and solutions for cancer and infectious diseases, better serving patients. | $187.4M / Series C / Jun 03, 2021 | |
MegaRobo
|
AI & Robotics Company based in Beijing,China. | Corporate Round / May 28, 2021 | |
|
MegaRobo
|
AI & Robotics Company based in Beijing,China. | $65M / Venture - Series Unknown / May 28, 2021 | |
Engine Biosciences
|
Engine Biosciences is a biotech company that applies machine learning to genomics for drug discovery.Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. The company's proprietary and patented technologies oriented around deciphering the complexity of biology networks includeboth high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming. This platform, developed through several years of research by our scientific founding and leadership team who include faculty members at MIT, Harvard, Mayo Clinic, and UCSD, dramatically accelerates and reduces costs of the R&D process for new medical therapies. We are actively applying the platform internally and with partners across a range of disease indications. | $43M / Series A / May 26, 2021 | |
OakMega
|
OakMega is an AI company helping businesses grow by building trusted customer relationships with real-time 1st-party data. | Series A / May 10, 2021 | |
| See all 49 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does WuXi AppTec invest in?
WuXi AppTec invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 49 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is WuXi AppTec's check size?
WuXi AppTec typically joins rounds of $6M–$90M at Series A, $21M–$130M at Series B and $30M–$187M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds WuXi AppTec participates in.
How do I contact WuXi AppTec?
Public channels for WuXi AppTec include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at WuXi AppTec?
The team at WuXi AppTec includes Edward Hu (Co-CEO), Ellis Chu (Chief Financial Officer) and Ge Li (Founder, Chairman and CEO), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
